Library — CHDR

Search

Filter

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: a randomized cross‐over trial

Bakker C, Prins S, Liptrot J, Hart EP, Klaassen ES, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Stevens J, Cross DM, Tasker T, Nathan PJ, Groeneveld GJ

BJCP, 2021 Apr

View publication
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study.

Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Doll RJ, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ

Alzheimer's research & therapy, 2021 Apr; 13(1):87

View publication
A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator.

den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, Grievink HW, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen VC, Hilt DC, Groeneveld GJ

British journal of clinical pharmacology, 2021 Feb

View publication
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.

Vissers MFJM, Heuberger JAAC, Groeneveld GJ

International journal of molecular sciences, 2021 Feb

View publication
False negatives in GBA1 sequencing due to polymerase dependent allelic imbalance.

den Heijer JM, Schmitz A, Lansbury P, Cullen VC, Hilt DC, Bonifati V, Groeneveld GJ

Scientific reports, 2021 Jan; 11(1):161

View publication
Experience in Genetic Counseling for Variants in Parkinson's Disease.

den Heijer JM, van Hilten JJ, Kievit AJA, Bonifati V, Groeneveld GJ

Movement disorders clinical practice, 2021 Jan; 8(1):33-36

View publication
First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M -receptor partial agonist for the treatment of dementias.

Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, van der Doef TF, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ

British journal of clinical pharmacology, 2020 Dec

View publication
Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study.

van Diemen MPJ, Hart EP, Abbruscato A, Mead L, van Beelen I, Bergheanu SC, Hameeteman PW, Coppen E, Winder JY, Moerland M, Kan H, van der Grond J, Webb A, Roos RAC, Groeneveld GJ

British journal of clinical pharmacology, 2020 Nov

View publication
Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine

Charlotte Bakker, Jasper van der Aart, Ellen P. Hart, Erica S. Klaassen, Kirsten R. Bergmann, Michiel J. van Esdonk, Denis G. Kay, Geert Jan Groeneveld

Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2020 Oct

View publication

«
1
2
3
4
5
6
7
8
...
18
19
»